Difference between revisions of "Alpha-methylacyl-CoA racemase"
Jump to navigation
Jump to search
| Line 1: | Line 1: | ||
[[Image:Atypical_small_acinar_proliferation_-_AMACR-CK34betaE12_-_alt_--_very_high_mag.jpg|thumb|right|AMACR positivity in [[ASAP]]. CK5/6-AMACR immunostain.]] | |||
'''Alpha-methylacyl-CoA racemase''', abbreviated '''AMACR''', is a commonly used [[immunostain]] in [[genitourinary pathology]]. | '''Alpha-methylacyl-CoA racemase''', abbreviated '''AMACR''', is a commonly used [[immunostain]] in [[genitourinary pathology]]. | ||
Revision as of 16:40, 11 December 2014
AMACR positivity in ASAP. CK5/6-AMACR immunostain.
Alpha-methylacyl-CoA racemase, abbreviated AMACR, is a commonly used immunostain in genitourinary pathology.
Positive
- Prostate adenocarcinoma.[1]
- Papillary renal cell carcinoma.[2]
- High-grade prostatic intraepithelial neoplasia.
Positive or negative
- Nephrogenic adenoma.
- Urothelial carcinoma - not useful for differentating prostate versus bladder.
Negative
See also
References
- ↑ Lloyd, MD.; Yevglevskis, M.; Lee, GL.; Wood, PJ.; Threadgill, MD.; Woodman, TJ. (Apr 2013). "α-Methylacyl-CoA racemase (AMACR): metabolic enzyme, drug metabolizer and cancer marker P504S.". Prog Lipid Res 52 (2): 220-30. doi:10.1016/j.plipres.2013.01.001. PMID 23376124.
- ↑ Molinié, V.; Balaton, A.; Rotman, S.; Mansouri, D.; De Pinieux, I.; Homsi, T.; Guillou, L. (Jun 2006). "Alpha-methyl CoA racemase expression in renal cell carcinomas.". Hum Pathol 37 (6): 698-703. doi:10.1016/j.humpath.2006.01.012. PMID 16733210.